Update shared on07 Aug 2025
Fair value Increased 18%Driven by a notable upward revision in consensus revenue growth forecasts and a modest improvement in net profit margin, Fortis Healthcare’s analyst price target has increased from ₹829.27 to ₹879.27.
What's in the News
- Fortis Healthcare to hold a board meeting to review unaudited Q1 FY26 results and consider changes affecting rights of debenture holders of its INR 15.5 billion listed debentures.
- IHH Healthcare Berhad announced a strategic collaboration for Fortis to manage operations of five Gleneagles India hospitals under an O&M agreement, aiming to enhance operational scale and unlock synergies, subject to relevant approvals.
- Fortis Healthcare, along with Manipal Health, is in discussions with global banks to raise up to INR 50 billion for bidding on Sahyadri Hospitals, which is being sold by Ontario Teachers' Pension Plan Board.
- Fortis Healthcare is expected to report Q1 2026 results on August 6, 2025.
Valuation Changes
Summary of Valuation Changes for Fortis Healthcare
- The Consensus Analyst Price Target has risen from ₹829.27 to ₹879.27.
- The Consensus Revenue Growth forecasts for Fortis Healthcare has significantly risen from 14.2% per annum to 16.3% per annum.
- The Net Profit Margin for Fortis Healthcare has risen slightly from 14.39% to 14.77%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.